Clinical Trial: Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS>=1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07524452) titled 'Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS>=1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma' on March 28.

Brief Summary: This study is a randomized, open-label, multicenter phase III trial designed to systematically evaluate the efficacy and safety of perioperative neoadjuvant and adjuvant therapy with Becotatug vedotin in combination with PD-1 inhibitor versus PD-1 inhibitor alone in patients with EGFR-positive, CPS >= 1 resectable locally advanced head and neck squamous cell carcinoma .

Study Start Date: Feb. 06

Study Type: INTE...